Christian Junghanss

TL;DR: Primary data showed superior efficacy for dasatinib compared with imatinib after 12 months, including significantly higher rates of complete cytogenetic response (CCyR), confirmed CCyR (primary end point), and major molecular response (MMR).

TL;DR: The therapeutic strategy could become a new standard of care after autologous stem-cell transplantation; however, prophylactic platelet transfusion should remain the standard for patients with acute myeloid leukaemia.

TL;DR: It is pointed out that mTORC1 inhibitors, either as a single agent or in combination with Akt inhibitors, could represent a potential therapeutic innovative strategy in B-pre ALL.

TL;DR: Azacitidine is active and well tolerated in elderly patients with newly diagnosed AML, and lower marrow blasts on day 15 of cycle 1, irrespective of pretreatment count, predicted subsequent response.

TL;DR: There were no differences in the efficacy and safety of itraconazole and fluconazole prophylaxis in neutropenic patients with haematological malignancies and no differences were detected between treatment groups in proven or suspected invasive fungal infections or other endpoints.